This study redefines the molecular classification of pulmonary neuroendocrine tumors through integrative multi-omics analysis, providing key molecular markers and potential therapeutic targets for precision diagnosis and treatment strategies of pulmonary carcinoids, with significant clinical implications especially for identifying high-risk patients.
Literature Overview
This article, 'Deep molecular profiling of lung neuroendocrine tumours and supra-carcinoids,' published in the journal Molecular Cancer, systematically investigates the molecular heterogeneity of pulmonary neuroendocrine tumors (NETs) and carcinoids. Based on multi-omics data from 319 fresh-frozen samples, combined with spatial transcriptomics and deep learning-based pathological image analysis, the research team identified four molecular subtypes, among which the newly defined sc-enriched group (i.e., supra-carcinoid) exhibits aggressive clinical behavior and distinct microenvironmental features. This work not only unifies previous molecular classification systems but also provides a clinically translatable molecular-morphological integrated classification framework.Background Knowledge
Pulmonary carcinoids are neuroendocrine tumors with rapidly increasing incidence but unclear etiology. Their clinical management is limited by the insufficient prognostic discrimination and inter-observer variability of the current WHO grading system (based on mitotic count and necrosis). Driver genes such as TP53 and RB1 are rarely mutated in pulmonary carcinoids, while mutations in MEN1 and BRAF exist but lack clear targeted therapeutic pathways, resulting in extremely limited treatment options. Furthermore, conventional morphology struggles to explain the paradoxical phenomenon where some low-grade tumors exhibit highly aggressive behavior, suggesting the existence of unrecognized high-risk biological subtypes. This study addresses these gaps by integrating genomic, transcriptomic, methylomic, and spatial omics data to systematically dissect the molecular architecture of lung NETs and explore whether supra-carcinoid represents an intermediate state bridging low-grade NETs and high-grade neuroendocrine carcinomas (e.g., SCLC, LCNEC), thereby filling critical knowledge gaps in the heterogeneity and evolutionary trajectory of pulmonary carcinoids.
Research Methods and Experiments
The research team constructed a large cohort of 319 pulmonary NETs (including paired normal tissues), performing whole-genome sequencing, transcriptome sequencing, DNA methylation arrays, and spatial transcriptomic analyses, integrating the data using MOFA and ParetoTI for multi-omics integration and prototype analysis. To validate the morphological discriminability of molecular subtypes, a deep learning model was applied for unsupervised patch clustering of whole-slide H&E images, with morphological features annotated by six pathologists. Additionally, tumor microenvironment and evolutionary trajectories were dissected using single-cell reference deconvolution, cell interaction analysis, and multi-region sequencing. Key evidence shows that the sc-enriched group not only shares molecular similarities with SCLC but also harbors driver events such as BRAF V600E and TERT amplification. Spatial transcriptomics revealed an ICAM1–ITGB2 interaction axis between LAP-like progenitor cells and macrophages, supporting a tumor-immune microenvironment co-driven oncogenic mechanism.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides clear subtype-specific therapeutic targets for drug development: for example, high expression of DLL3 in Ca A1 suggests potential sensitivity to DLL3-targeted therapies (e.g., Rova-T); the presence of BRAF V600E and TERT amplification in the sc-enriched group supports clinical trials of BRAF/MEK inhibitors. Moreover, the sc-enriched group is significantly enriched for T-cell inflammation signatures, suggesting potential responsiveness to PD-1 inhibitors and offering new directions for immunotherapy strategies.
In clinical monitoring, this molecular classification can be implemented clinically using IHC markers (e.g., ASCL1, HNF1A, OTP), aiding in the identification of high-risk patients and guiding personalized follow-up. Additionally, deployment of deep learning models could enable automated initial screening, improving diagnostic consistency.
For disease modeling, this study supports the development of genetically engineered mouse models carrying BRAF V600E, TERT amplification, and chromothripsis to simulate the evolution of supra-carcinoid. Furthermore, the rapid proliferation and phenotypic plasticity of PDTO models provide an ideal platform for studying resistance mechanisms and drug screening.
Conclusion
This study systematically reconstructs the molecular landscape of pulmonary carcinoids using deep multi-omics and spatial resolution technologies, establishing supra-carcinoid as an aggressive subtype with distinct biological behaviors and microenvironmental characteristics. Its molecular continuity with high-grade neuroendocrine carcinomas challenges the traditional dichotomy between NET and NEC, proposing a dynamically evolving tumor model. From bench to bedside, this research provides a clinically actionable morphology-molecular integrated classification system, enhancing diagnostic objectivity and reproducibility through deep learning-assisted identification of high-risk cases. More importantly, it reveals targetable nodes such as DLL3, BRAF, and TERT, opening precision therapy avenues for pulmonary carcinoid patients who currently lack effective treatments. In the future, prospective clinical trials based on this classification will validate its value in treatment selection and outcome prediction, potentially reshaping the care paradigm for pulmonary carcinoids and enabling a transition from morphology-based to mechanism-driven precision medicine.
